Scancell Holdings (SCLP)


Latest News

Scancell to collaborate with BioNTech

RNS Number: 1654B Scancell Holdings Plc 09 January 2018 09 January 2018 Scancell Holdings Plc ("Scancell" or the "Company") Scancell to collaborate with BioNTech to investigate T cell receptor based therapeutics for the treatment of cancer Agreement expands potential therapeutic utility of Moditope to adoptive T cell therapy Scancell Holdings plc, ('Scancell' or th...

Scancell forms partnership with Cancer Research

Scancell, a developer of immunotherapies for the treatment of cancer, has partnered with the charity Cancer Research UK...

Scancell and CRUK to advance cancer immunotherapy

RNS Number: 2811Z Scancell Holdings Plc 14 December 2017 14 December 2017 Scancell Holdings Plc ("Scancell" or the "Company") Scancell and Cancer Research UK collaborate to advance novel cancer immunotherapy into clinical trials Cancer Research UK to progress SCIB2 into a Phase 1/2 study for patients with a range of solid tumours Scancell Holdings PLC, a...

Trends and Targets for 8/12/2017

FTSE FOR FRIDAY (FTSE:UKX) Sometimes, the utter boredom inflicted by the market leads one down a strange path. Th...

All News

09-01-18Scancell to collaborate with BioNTechRNS
14-12-17Scancell forms partnership with Cancer ResearchStockMarketWire
14-12-17Scancell and CRUK to advance cancer immunotherapyRNS
07-12-17Trends and Targets for 8/12/2017Trends and Targets
11-10-17Result of AGMRNS
10-10-17Directorate ChangeRNS
14-09-17Notice of AGMRNS
13-09-17Weak mining and consumer stocks hit FTSEStockMarketWire
13-09-17Scancell reports good progress in development of Modi-1StockMarketWire
13-09-17Final ResultsRNS
11-09-17Presents Moditope Data at Immunotherapy ConferenceRNS
29-08-17Oncimmune and Scancell Present Autoantibodies DataRNS
11-07-17Scancell notes continued progress on SCIB1StockMarketWire
11-07-17Continued Progress on SCIB1RNS
26-06-17Scancell notes ImmunoBody patent granted in EuropeStockMarketWire
26-06-17DNA ImmunoBody Patent Granted in EuropeRNS
22-05-17Holding(s) in CompanyRNS
19-05-17Holding(s) in CompanyRNS
19-05-17Holding(s) in CompanyRNS
11-05-17Results of PlacingRNS
11-05-17Scancell proposes raising up to £5.0mStockMarketWire
11-05-17Proposed Placing to Raise up to ?5.0 millionRNS
13-04-17Scancell changes registered officeStockMarketWire
13-04-17Change of Registered OfficeRNS
20-03-17Immuno-Oncology Summit Europe 2017RNS
13-03-17Scancell eyes fundraising for Phase II SCIB1 trialStockMarketWire
13-03-17Hardman Research: SCIB development updateRNS
01-03-17Holding(s) in CompanyRNS
31-01-17Scancell widens H1 pretax lossStockMarketWire
31-01-17Interim ResultsRNS
30-01-17Scancell in partnership to advance lung cancer clinical trialsStockMarketWire
30-01-17Partnership to Advance Lung Cancer Clinical TrialsRNS
03-01-17Research Update - AmendmentRNS
03-01-17Scancell Holdings issues research updateStockMarketWire
03-01-17Research UpdateRNS
14-11-16World Immunotherapy Congress and Biotech and MoneyRNS
18-10-16Results of AGMRNS
10-10-16Preparing SCIB2 for clinical study in lung cancerRNS
26-09-16Hardman Report: New frontiers in T-cell activationRNS
23-09-16Notice of AGM - AmendmentRNS

RSS feeds

  • Editorial news feed for LSE:SCLP Editorial
  • Regulatory news feed for LSE:SCLP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account